Abstract Number: 2380 • ACR Convergence 2024
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…Abstract Number: 2398 • ACR Convergence 2024
The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus
Background/Purpose: To identify whether serum 25-Hydroxyvitamin D (25(OH)D) level in first-trimester(before13 weeks of gestation) maternal is associated with pregnancy outcomes in patients with systemic lupus…Abstract Number: 2416 • ACR Convergence 2024
The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…Abstract Number: 2433 • ACR Convergence 2024
Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination
Background/Purpose: SLE patients have increased risk of invasive pneumococcal disease due to immune dysregulation and drugs used in these patients. EULAR 2019 recommendation suggest sequential…Abstract Number: 2578 • ACR Convergence 2024
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Background/Purpose: There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and systemic lupus erythematosus (SLE) pathophysiology. Dual inhibition of TLR7/8 will modulate innate…Abstract Number: 2663 • ACR Convergence 2024
ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…Abstract Number: 0119 • ACR Convergence 2024
Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis
Background/Purpose: Antiphospholipid syndrome (APS) is closely linked with Systemic Lupus erythematosus (SLE) and can influence patient outcomes. The interplay between APS and SLE, including the evolution…Abstract Number: 0182 • ACR Convergence 2024
Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune condition that disproportionally affects individuals from racial and ethnic minority groups with more than 95%…Abstract Number: 0217 • ACR Convergence 2024
Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…Abstract Number: 0611 • ACR Convergence 2024
Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 150
- Next Page »